Agilera’s vision is to realise the cancer medicine of tomorrow. We work closely with our partners to take new, innovative radiopharmaceuticals from concept to patient.
Agilera was launched from IFE in 2023
Agilera works across the entire value chain for developing new radiopharmaceuticals, from the preclinical phase to commercial production.
By bringing together the entire CDMO activity in a single, new company, we are strengthening our unique position as a global supplier of radiopharmaceuticals.
Agilera is attractively situated near Oslo, with easy access to Oslo Airport. We have options for expanding our site with a new GMP facility.